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A B S T R A C T
Due to the technical innovations in generating bispecific antibodies (BsAbs) in recent years, BsAbs have become
important reagents for diagnostic and therapeutic applications. However, the difficulty of producing a hetero-
dimer consisting of two different arms with high yield and purity constituted a major limitation for their ap-
plication in academic and clinical settings. Here, we describe a novel Fc-containing BsAb format (Fab × sdAb-
Fc) composed of a conventional antigen-binding fragment (Fab), and a single domain antibody (sdAb), which
avoids heavy-light chain mis-pairing during antibody assembly. In this study, the Fab x sdAb-Fc BsAbs were
efficiently produced by three widely used heavy-heavy chain heterodimerization methods: Knobs-into-holes
(KIH), Charge-pairs (CP) and controlled Fab-arm exchange (cFAE), respectively. The novel Fab x sdAb-Fc format
provided a rapid and efficient strategy to generate BsAb with high purity and a unique possibility to further
purify desired BsAbs from undesired antibodies based on molecular weight (MW). Compared to conventional
BsAb formats, the advantages of Fab x sdAb-Fc format may thus provide a straightforward opportunity to apply
bispecific antibody principles to research and development of novel targets and pathways in diseases such as
cancer and autoimmunity.
1. Introduction
Bispecific antibodies (BsAbs) have been considered promising
cancer therapeutics for a long period of time. The first artificial anti-
body-based molecule with the ability to bind to two different antigens
at the same time was described by Nisonoff's team in 1960s, which
marked the launch of a long BsAb generation campaign (Nisonoff et al.,
1960). Compared to monospecific monoclonal antibodies, the potential
advantages of BsAbs are undisputed. When applied to cancer therapy,
BsAbs have shown potential to redirect specific immune cells to tumour
cells to enhance tumour killing (Staerz et al., 1985). Furthermore, given
that cancer is a complex, multifactorial and heterogenic disease invol-
ving many disease-driving proteins and cross-talking pathways, BsAbs
can be used to target two antigens that each are not necessarily tumour-
specific but targeting the combination improves selectivity of tumour
targeting over normal tissues (Mazor et al., 2015a) (Mazor et al., 2017).
Moreover, dual targeting could be useful to modulate two separate
functional pathways in the tumour, or to avoid resistance to the treat-
ment (Lopez-Albaitero et al., 2017) (Moores et al., 2016).Nevertheless,
BsAbs have not yet stimulated broad interest of pharmaceutical com-
panies until recent years due to challenges in BsAb manufacturing
(Garber, 2014). By the end of 2017, compared to the number of 57
clinically approved mAbs, there were only two BsAbs on the market
(Grilo and Mantalaris, 2019). The major challenge in the development
of BsAbs is the difficulty in producing a pure BsAb without the presence
of contaminating antibody by-products such as non-functional or
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monospecific molecules formed during assembly.
Over the past two decades, with the development of protein and
gene engineering, over 100 different formats of BsAbs have become
available which fall into four classes: Fc containing asymmetric archi-
tecture, Fc-less asymmetric architecture, Fc containing symmetric ar-
chitecture and Fc-less symmetric architecture (Brinkmann and
Kontermann, 2017) (Ha et al., 2016). The diversification of BsAb for-
mats allows researchers to modify the size, half-life, valency, flexibility,
and biodistribution of BsAb for applications of different purposes. In
many cases, the Fc region is needed to ensure a relatively long phar-
macokinetic in vivo half-life and the ability to induce secondary im-
mune functions of a given BsAb, such as Antibody-dependent cell-
mediated cytotoxicity (ADCC), Antibody-dependent cellular phagocy-
tosis (ADCP) and Complement-dependent cytotoxicity (CDC). To form a
Fc containing asymmetric BsAb, several methodologies have been de-
veloped to enforce the correct association of the two different heavy
chains of a BsAb during cellular expression. Well-known examples are
knobs-into-holes (KIH) (Merchant et al., 1998) (Atwell et al., 1997),
charge-pairs (CP) (Gunasekaran et al., 2010), leucine zipper induced
heterodimerization (LUZeY) (Wranik et al., 2012), strand-exchange
engineered domain CH3 heterodimers (SEEDbody) (Davis et al., 2010),
and HA-TF (Moore et al., 2011).
These heterodimerization methods solved the heavy-heavy chain
mis-pairing problem to a great extent, but inadvertent mis-pairing of
heavy-light chain still remained a major limitation. One straightforward
method to overcome heavy-light chain mis-pairing is to share common
light chain by two different heavy chains (Merchant et al., 1998)
(Jackman et al., 2010) (Krah et al., 2017). The latter approach provides
a challenge when using pre-existing and validated (‘benchmark’) par-
ental monospecific antibodies, and parental candidates must be (re-)
generated to fit the common light chain approach. Alternatively, to
enforce the correct heavy-light chain pairing, some approaches in-
troduced amino acid mutations at the contact points of VH/VL, CH1/CL
or both (Igawa et al., 2010) (Lewis et al., 2014) (Bönisch et al., 2017);
some approaches exchanged the VH-VL or the CH1-CL domains by
domain crossover between the heavy and light chain Fab domains such
as CrossMab (Schaefer et al., 2011), DuetMab (Mazor et al., 2015b) and
orthogonal Fab (Lewis et al., 2014). Alternatively, the heavy-light chain
mis-pairing can be circumvented by producing the BsAb out of two
parental mAbs as demonstrated for the Duobody (DB) technology which
makes use of controlled Fab-arm exchange (cFAE) methodology to
achieve correct heavy-heavy chain heterodimerization (Labrijn et al.,
2013).
Importantly, in addition to introducing enhanced immunogenicity
risk the extensive protein engineering required for most of these ap-
proaches to improve physicochemical, biological characteristics and
even affinity lead to the requirement for additional analytical and
quality testing (Atwell et al., 1997) (Masuda et al., 2006) (Chailyan
et al., 2011) (Herold et al., 2017).
In this study, we describe a novel format of BsAb, the Fab x sdAb-Fc,
which combines a conventional antigen-binding fragment (Fab) with a
single domain antibody (sdAb), both linked to Fc domains optimized for
heavy-heavy chain heterodimerization. This novel format avoids the
issue of heavy-light chain mis-pairing and can be used in combination
with common heavy-heavy chain heterodimerization strategies. As a
proof of concept, we generated BsAbs, in a mouse IgG2a format, specific
for two tumour antigens, mEGFR and mPSMA, using well established
cFAE, CP and KIH heavy-heavy chain heterodimerization methods.
Since the sdAb domain does not bind light chains, the expressed light
chain region of the BsAb can only associate with its corresponding
heavy chain. Our results show that the Fab x sdAb-Fc BsAb can be
generated with high purity, and the products are stable by all quality
testing applied suggesting that this novel BsAb format constitutes a
convenient and promising technology for exploration of bispecific
concepts in the potential treatment of cancer, autoimmune, in-
flammatory and other diseases.
Fig. 1. Schematic diagram of mouse IgG2a-based Fab x sdAb-Fc BsAbs generated by using (A) controlled Fab-arm exchange (cFAE), (B) charge-pairs (CP) and (C)
knobs-into-holes (KIH); (D) Design of bispecific control antibodies using the cFAE method.
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2. Materials and methods
2.1. Design of vectors
The anti-mEGFR sdAb (RR359) has been described before (Zaiss
et al., 2013) and the amino acid sequence of anti-mPSMA antibody
(Sam103) was obtained from patent US20170342169A1. The sequence
of isotype control antibodies was obtained from the protein data bank,
which PDB IDs were 2NY7 (B12, anti-gp120) and 4B50 (2H10, anti-
gp41), respectively. The amino acid mutations introduced to each an-
tibody to allow heavy-heavy chain heterodimerization are depicted in
Fig. 1 for the various heterodimerization technologies.
In short, for the Duobody (DB) method using the controlled Fab arm
exchange, T370K and K409R point mutations were introduced to the
CH3 region of a heavy chain only antibodies, F405L and R411T point
mutations were introduced to the CH3 region of the conventional an-
tibodies. Parental mAb expression vectors were constructed by de novo
synthesis (GeneArt). For the CP method, E356K and D399K point mu-
tations were introduced to the CH3 region of the heavy chain only
antibody, K392D and K409D point mutations were introduced to the
CH3 region of the conventional antibody. For the KIH method, T366S,
L368A and Y407V point mutations were introduced to the CH3 region
of the heavy chain only antibody, T366W point mutation was in-
troduced to the CH3 region of the conventional antibody.
Between the sdAb and the Fc part of the heavy chain only antibody
(HcAb), a camelid/mouse chimeric linker was introduced (EPKIPQP-
QPKPQPQPQPQPKPQPKPCPPCKCPAPNLLGG). The expression vectors
of these antibodies were constructed by de novo synthesis (GeneArt).
Amino acid sequences of all antibodies are given in Supplementary
Table 1.
2.2. Expression and purification of BsAbs by knobs-into-holes and charge-
pairs
The FreeStyle™ 293-F cells (Invitrogen) were grown in FreeStyle
293 Expression medium, (Invitrogen). Each relevant vector (described
in Supplementary Table 1) was co-transfected into FreeStyle™ 293-F
cells using the 293fectin reagent (Invitrogen) according to the condi-
tions recommended by the manufacturer. 7 days post-transfection, cell
suspensions were collected and centrifuged for 15 min at 2500 xg. The
supernatant was passed through a 0.22 μm filter and stored at 4 °C. The
amount of BsAbs in the supernatant was measured by a Cedex bioa-
nalyzer (Roche). The supernatant was then mixed with MabSelect SuRe
LX resin (GE Lifesciences) and rotated overnight at 4 °C. After overnight
capturing, the BsAbs were purified from the supernatant by affinity
chromatography using Pierce™ Centrifuge Columns (ThermoFisher
Scientific) and re-buffering to PBS using PD-10 Desalting Columns (GE
healthcare) according to the manufacturer's instructions. Antibody
concentration was calculated based on Beer-Lambert Law, A = ε * b *
c，(A is the A280 absorbance, b is the path length, c is the analyte
concentration and ε is the wavelength-dependent molar absorptivity
coefficient with units of M−1 cm−1). A280 absorbance of each antibody
was measured by spectrophotometry using a Nanodrop ND-1000
system.
2.3. Generation of BsAbs by controlled fab-arm exchange
Parental antibodies were produced under serum-free conditions by
co-transfecting relevant heavy and light chain expression vectors in
FreeStyle™ 293-F cells, using 293fectin™ according to the manufac-
turer's instructions. Antibodies were purified by protein A affinity
chromatography, dialyzed overnight to PBS, and filter-sterilized over
0.22 μM filters. Antibody concentration was calculated as previously
described.
The bispecific antibody was produced by controlled Fab-arm ex-
change using the two purified bivalent parental antibodies, each with
the respective complementary mutations: T370K, K409R or F405L,
R411T (specific to mouse IgG2a isotype) (Labrijn et al., 2017). Equi-
molar amounts of relevant parental antibodies were mixed and in-
cubated with 2-Mercaptoethylamine (2-MEA; Sigma) at a final con-
centration of 2mg/mL total antibody in PBS, with the final
concentration of 2-MEA being 75mM. The mixtures were incubated for
5h at 31 °C. To remove 2-MEA, the mixtures were buffer-exchanged
against PBS using Slide-A-Lyzer cassettes (ThermoFisher Scientific).
Samples were stored overnight at 4 °C to allow for the re-oxidation of
the disulfide bonds. Antibody concentration was calculated as pre-
viously described.
Three Fab x sdAb-Fc bispecific control antibodies were designed 1)
DB.gp120 x EGFR containing the EGFR monovalent single domain an-
tibody combined with a non-relevant isotype arm (antibody B12, anti-
HIV-gp120); 2) DB.PSMA x gp41 containing the PSMA monovalent
antibody combined with a non-relevant isotype single domain antibody
arm (antibody 2H10, anti-HIV-gp41); 3) Non-functional bispecific
DB.gp120 x gp41 containing single-domain antibody arm gp41 com-
bined with arm gp120. The three bispecific control antibodies were
produced by cFAE.
2.4. High performance size-exclusion chromatography (HP-SEC)
Aggregation and degradation of BsAbs was quantified by HP-SEC
using a YMC-pack Diol-200 column (YMC) with Agilent 1100 series
HPLC system. Separation was carried out in 10 mM HEPES, pH 7.4,
containing 150 mM NaCl, 3.4 mM EDTA and 0.05% Tween 20.
2.5. SDS-page
Formation of BsAbs was analysed using SDS-PAGE analysis in re-
ducing and non-reducing conditions. Samples were diluted to a final
concentration of 0.5 mg/mL with respectively Laemmli Sample Buffer
(Bio-Rad) for analysis in non-reducing conditions or Laemmli Sample
Buffer containing 200 mM DTT for analysis in reducing conditions.
Samples were heated at 99 °C for 5 min. 5 μg of antibody and 10ul
Precision Plus Protein All Blue Standards (Bio-Rad) were loaded onto
NuPAGE® 4–12% Bis-Tris Gel (Invitrogen). Electrophoresis was run in
NuPAGE® MOPS SDS Running Buffer (Invitrogen) at 150 V for 90 min
for the non-reduced samples and NuPAGE® MES SDS Running Buffer
(Invitrogen) at 150 V for 60 min for the reduced samples. Gels were
stained using Coomassie protein assay reagent (Thermo Scientific),
destained with distilled water and scanned using ChemiDoc™ Touch
Imaging System (Bio-Rad).
2.6. Capillary electrophoresis sodium dodecyl sulfate (CE-SDS)
The purity of all BsAbs were tested by CE-SDS in non-reduced mode.
CE-SDS analysis was carried out on a CE system PA800 Plus machine
(Beckman Coulter). Samples were diluted to 1 mg/mL with 10 kDa
internal standard and 15 mM iodoacetamide in SDS-MW sample buffer
and heated to 70 °C for 10 min. 95 μL were transferred into sample vials
and loaded into the machine. Separations were performed in a bara-
fused silica 50 μm I.D capillary at 22 °C. Effective separation length was
20 cm, run time 30 min and antibody fragments detected at a wave-
length of 220 nm. The capillary was flushed with 0.1 M HCl, NaOH,
water and running buffer before sample loading at 5 kV for 20 s. Data
analysis was carried out with the 32Karat software (version 9.2).
2.7. Capillary isoelectric focusing (cIEF)
cIEF was performed on a Beckman Coulter PA 800 Plus using an
amine-coated (eCAP™), 50 μm ID × 30 cm capillary. An ampholyte
mixture containing 2.5% (w/v) Pharmalyte pH 3–10, 0.2% (w/v) (hy-
droxypropyl) methyl cellulose, 0.3% (v/v) N,N,N′,N′-tetra-
methylethylenediamine, and pI 10 marker was combined with antibody
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diluted in water to obtain a final antibody concentration of 0.3 mg/mL.
Analysis was performed at 25 kV and 20 °C with a 15 min focusing
period under normal polarity during which isoforms migrate to their pI
in the pH gradient. This was followed by a 30 min mobilization step
using the Bio-Rad chemical mobilizer with the UV detector set at
280 nm.
2.8. Generation of CHO·K1 stable cell line
The CHO·K1 cells (ATCC) were grown in Dulbecco's Modified Eagle
Medium: Nutrient Mixture F-12 (DMEM/F12), supplemented with 5%
New Born Calf Serum (Biowest). 24 μg of pCI-neomEGFR (UniProtKB -
Q01279) and pCI-neomPSMA (UniProtKB - O35409) plasmids con-
structed by de novo synthesis (GeneArt) were transfected into 5 × 106
cells using lipofectamine 2000 reagent (Invitrogen) according to the
conditions recommended by the manufacturer. Subsequently, trans-
fected cells were cultured in complete cell culture medium (DMEM/
F12 + 5% New Born Calf Serum) with addition of 0.8 mg/ml G418 for
14 days. Selected cells were then stained by rabbit anti-mEGFR-PE (Cell
Signalling Technology) or anti-mPSMA antibodies (Sam103), respec-
tively. Positive stained cells were seeded into 96-well plate for clone
formation by single cell sorting on a FACSMelody (BD). The clones
CHO/mPSMA-HA(A6) and CHO/mEGFR-LA(A1) stably expressed
mPSMA or mEGFR, respectively, for more than 2 months and were
further used for the present study.
2.9. Cell binding assays
CHO/mEGFR and CHO/mPSMA cells were detached and washed 3
times with FACS buffer (PBS + 1% BSA + 1 mM EDTA). For CHO/
mEGFR binding assay, BsAb DB.PSMA x EGFR, BsAb DB.gp120 x gp41
and EGFR HcAb were added in 5-fold serial dilution in FACS buffer,
incubated on ice for 45 min. For CHO/mPSMA binding assay, BsAb
DB.PSMA x EGFR, BsAb DB.gp120 x gp41 and PSMA mAb were added
in 5-fold serial dilution in FACS buffer, incubated on ice for 45 min.
Secondary antibody staining was performed using rat-anti-mouse IgG2a
antibody conjugated with FITC (Biolegend) in 1:500 dilution in FACS
buffer on ice for 45 min. Samples were analysed by FACS Canto™ II
(BD) using the software program BD FACSDiva. Ten thousand events
were collected.
Flow cytometry was used to determine the simultaneous binding
activity of BsAb DB.PSMA x EGFR to mEGFR and mPSMA using stable
transfected cell lines (CHO/mPSMA and CHO/mEGFR). In order to
prepare single-cell suspension, cells were detached from flasks using
cell dissociation buffer enzyme-free, PBS-based (Gibco). Cells were
washed cells twice with PBS and CHO/mPSMA and CHO/mEGFR cells
were labelled by cell staining dye eFluor 450 or 670 (eBioscience),
respectively, according to the conditions recommended by the manu-
facturer. 5 × 104 cells of cell staining dye eFluor 450 or 670 labelled
cell line were mixed in 100 μl FACS buffer (PBS + 1%BSA + 1 mM
EDTA) and cells were incubated with bispecific control antibodies
(50 μg/ml, equivalent to 390.63 nM) or 5-fold serial dilution of
BD.PSMA x EGFR (0.0032 μg/ml to 50 μg/ml, equivalent to 0.005 nM
to 390.63 nM) at 4 °C for 45 mins. The stained cells were analysed on a
FACS Canto™ II (BD) using the software program BD FACSDiva. Ten
thousand events were counted. While the FACS CantoTM II counted
every singlet and each cluster as one event, it was unclear from this
analysis whether cellular clusters were formed by two cells(doublets),
three cells (triplets) or even more, therefore the term “percentage of
cellular cluster events” was used to quantify our results.
2.10. Octet
mEGFR-His recombinant protein (R&D systems) was diluted to
50 mM in 10 mM acetate pH 5.0 (ForteBio) and loaded on NHS/EDC
activated AR2G biosensors (ForteBio). BsAb DB.PSMA x EGFR and
bispecific control antibodies were diluted to 20 μg/mL in 10× kinetic
buffer (ForteBio) and associated to mEGFR-His protein. mPSMA-His
recombinant protein (Sino Biologicals) was diluted to 50 mM in 10×
kinetic buffer and associated to each BsAb. Binding kinetics were
measured by Octet system according to the manufacturer's instructions
(ForteBio). Data was analysed using Data analysis software HT V10.0
(ForteBio).
3. Results
3.1. Design and expression of BsAbs
To test whether Fab x sdAb-Fc format BsAbs, which combine a
conventional antigen-binding fragment (Fab) with a single domain
antibody (sdAb) and a mouse IgG2a Fc, can be produced efficiently, we
generated Fab x sdAb-Fc BsAbs, using three well-known heavy chain
heterodimerization strategies, i.e. cFAE, CP, or KIH, respectively. For
the cFAE strategy, parental monospecific bivalent antibodies (T370K
and K409R for anti-EGFR antibody RR359; F405L and R411T for anti-
PSMA antibody Sam103) were first expressed separately. The BsAb
duobody DB.PSMA x EGFR was produced in a second step by cFAE from
the purified bivalent parental antibodies (Fig. 1A). In case of the CP and
KIH strategies, the CP mutations (K392D and K409D for CH3 domain of
anti-PSMA antibody, E356K and D399K for CH3 domain of anti-EGFR
antibody) and KIH mutations (T366W for CH3 domain of anti-PSMA
antibody, T366S, L368A and Y407V for CH3 domain of anti-EGFR an-
tibody) were introduced into the corresponding expression vectors,
respectively. Relevant heavy chain and light chain expression vectors
CP mutations or KIH mutations were co-transfected into FreeStyle™
293-F cells, respectively. The BsAbs CP.PSMA x EGFR and KIH.PSMA x
EGFR were expressed and purified as described in method 2.2 (Fig. 1B-
C). The anti-gp120 (HIV) Fab arm and anti-gp41 (HIV) sdAb were used
to generate bispecific control antibodies by cFAE (Burton et al., 1994)
(Hulsik et al., 2013) (Fig. 1D).
3.2. Purity evaluation of BsAbs
In order to determine the purity of Fab x sdAb-Fc format BsAbs, we
performed Capillary Electrophoresis Sodium Dodecyl Sulfate (CE-SDS)
analysis. Under non-reducing conditions, the BsAbs generated by cFAE,
CP and KIH showed clear separation from parental antibodies with a
95.9%, 94.6% and 88.9% purity for DB.PSMA x EGFR, CP.PSMA x
EGFR or KIH.PSMA x EGFR, respectively. (Fig. 2A-C). The purity of
three bispecific control antibodies DB.PSMA x gp41, DB.gp120 x EGFR,
and DB.gp120 x gp41 was also evaluated by CE-SDS showing 94.8%,
94.2%, and 94.5% purity, respectively (data not shown). These data
demonstrate that Fab x sdAb-Fc format BsAbs can be generated effi-
ciently, and with high quality, using various heavy chain hetero-
dimerization strategies. The BsAb KIH.PSMA x EGFR, which was pro-
duced with a relative low purity (88.9%), was produced by KIH using
mutations T366W in the “knob” heavy chain and T366S, L368A, Y407V
in the “hole” heavy chain (Fig. 1C). By introducing two additional
mutations (S354C in the “knob” heavy chain and Y349C in the “hole”
heavy chain) such a construct is expected to further increase the effi-
ciency of heterodimerization and thus improve the purity of this BsAb
construct (Merchant et al., 1998).
Other than hydrophobic interaction chromatography (HIC), Cation
exchange chromatography (CIEX), Liquid chromatography–mass spec-
trometry (LC-MS), and CE-SDS, SDS-PAGE is a convenient and low
demand in equipment method to assess the successful formation and
estimate the purity of the Fab x sdAb-Fc BsAb format. Thus, SDS-PAGE
analysis of each purified BsAb was performed. Under non-reducing
conditions, the desired BsAbs are expected to show a predominant band
with a MW of ~127 kDa, whereas parental antibodies should show
predominant bands with a MW of ~93 kDa or ~ 163 kDa, respectively
(Fig. 2D). For BsAb CP.PSMA x EGFR and BsAb KIH.PSMA x EGFR,
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additional minor bands were detected at a size of ~160 kDa, which
indicated a minor contamination of the parental PSMA mAb in this
batch. Under reducing conditions, one band for EGFR HcAb, two bands
for PSMA mAb and three bands for BsAbs were detected, as expected
(Fig. 2E). The bands at ~50 kDa detected in BsAbs and PSMA mAb
represent the heavy chain of the PSMA mAb, while the MW bands at
~46 kDa detected in EGFR HcAb and BsAbs represent the heavy chain
of the EGFR HcAb. The bands at ~25 kDa detected in BsAbs and PSMA
mAb represent the light chain of the PSMA mAb.
Taken together, these data indicate that BsAbs can be efficiently
generated with high purity. Additionally, due to the MW difference
between BsAbs and parental antibodies, this format of BsAb can be
readily further purified from undesired by-products based on MW by
preparative Size Exclusion Chromatography.
3.3. Monomericity evaluation of BsAbs
To further analyse the aggregation and degradation level of BsAbs in
our purified batches, we performed analytical Size Exclusion
Chromatography (HP-SEC). After HP-SEC gel filtration, a predominant
peak with an area of 99% for BsAb DB.PSMA x EGFR, 98.5% for BsAb
CP.PSMA x EGFR and 98.4% for BsAb KIH.PSMA x EGFR was detected
(Supplementary Fig. 1). The aggregation and degradation level of three
bispecific control antibodies DB.PSMA x gp41, DB.gp120 x EGFR, and
DB.gp120 x gp41 were also evaluated by HP-SEC which showed 98.8%,
98.8%, and 99% monomericity, respectively (data not shown).
3.4. BsAbs analysis for isoelectric point
Generated BsAbs and parental antibodies were further analysed by
Capillary Isoelectric Focusing cIEF (Fig. 3). The BsAbs and parental
antibodies showed clearly different isoelectric points (pI). We observed
that the peaks of BsAbs were not detected precisely in the middle of the
peaks of two parental antibodies but were closer to the Sam103 peaks.
The peak pattern in this novel BsAb format can be explained by the
different mass contribution of each parental antibodies (~163 kDa
versus ~93 kDa).
3.5. Binding activity of BsAbs
To test the binding activity of each arm of the BsAbs, stably trans-
fected CHO/mEGFR and CHO/mPSMA were generated and used for
binding assays. Binding activity of BsAb DB.PSMA x EGFR and parental
antibodies specific for mEGFR or mPSMA were determined by flow
cytometry, using unlabelled primary antibodies followed by FITC-la-
belled secondary antibody for detection. BsAb DB.PSMA x EGFR
showed dose-dependent binding to both antigens. Monovalent binding
activity of BsAb DB.PSMA x EGFR to CHO/mEGFR cells showed relative
similar potency to bivalent binding by EGFR HcAb (EC50 0.87 nM
versus 0.28 nM) (Fig. 4A-B). For mPSMA binding, BsAb DB.PSMA x
EGFR showed strong reduction in binding to CHO/mPSMA compared to
the parental bivalent PSMA mAb (EC50 219 nM versus 0.32 nM)
(Fig. 4C-D). These data demonstrate that each antibody retained its
specificity within the bi-specific construct. In addition, and in contrast
to the EGFR specific sdAb RR359, the Sam103 PSMA antibody depends
on avidity for high affinity binding to its target.
Fig. 2. CE-SDS and SDS-PAGE analysis for the various Fab x sdAb-Fc BsAb formats. (A-C) Purity of (A) DB.PSMA x EGFR, (B) CP.PSMA x EGFR and (C) KIH.PSMA x
EGFR evaluated by CE-SDS. 10 kDa standard marker was used for the calibration of retention time for each trace. Numbers represent percentage of BsAb product
(middle red peaks). The peaks of parental antibody were shown in black(EGFR) or blue(PSMA) respectively; (D-E) Detection and separation of BsAbs and parental
antibodies by coomassie blue staining of SDS-PAGE under (D) non-reducing or (E) reducing condition. Lane 1, MW ladder; lane 2, EGFR HcAb; lane 3, KIH.PSMA x
EGFR; lane 4, CV.PSMA x EGFR; lane 5, DB.PSMA x EGFR; lane 6, PSMA mAb. (For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
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Remarkably, a qualitative examination of the binding curves re-
vealed a differential staining plateau for the two EGFR-specific anti-
body constructs. At a saturated concentration, BsAb DB.PSMA x EGFR
binding to CHO/mEGFR cells plateaued at an MFI of ~1250, which was
approximately 2 times as high as the plateau value for EGFR HcAb,
which had an MFI of ~750 (Fig. 4A). The differences between MFI
plateau reached by each antibody construct might be due to the dif-
ference between monovalent and bivalent binding, to be definitively
confirmed using monovalent parental controls. In case of monovalent
binding, one Ab construct binds one receptor. However, in case of bi-
valent binding one Ab construct is capable of binding two receptors
resulting in a lower absolute amount of cell bound antibody. Corre-
spondingly, in this experimental set-up, the higher staining plateau for
BsAb compared to HcAb is likely the result of pure monovalent binding
by the BsAb versus substantial bivalent binding for HcAb.
Combined, these data demonstrate that each arm of BsAb DB.PSMA
x EGFR maintained the binding activity to its corresponding antigen.
3.6. Simultaneous binding of BsAb
To determine whether our bi-specific constructs retained their ca-
pacity to bind to both antigens simultaneously, we performed bio-layer
interferometry (BLI), using an Octet machine, and physical cell-brid-
ging experiments, using FACS analysis. The binding characteristics of
the BsAb DB.PSMA x EGFR and three bispecific control antibodies to
recombinant mEGFR-His and mPSMA-His were analysed using Octet. In
Fig. 3. cIEF analysis for the Fab x sdAb-Fc BsAbs. (A) DB.PSMA x EGFR, (B) CP.PSMA x EGFR (C) KIH.PSMA x EGFR and parental antibodies. A gel filtration standard
(protein pI 10) was included for the calibration of retention time for each trace. The BsAbs are shown in red (middle line in each diagram). The parental antibodies
are shown in blue for anti-PSMA mAb (top line in each diagram) and black for anti-EGFR HcAb (bottom line in each diagram), respectively. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
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Fig. 4. Flow cytometry analysis of BsAbs and parental antibodies binding on CHO/mEGFR or CHO/mPSMA cells in a dose-dependent fashion. (A-B) CHO/mEGFR
cells stained by parental anti-EGFR HcAb, DB.PSMA x EGFR or control antibody DB.gp120 x gp41 respectively. (C-D) CHO/mPSMA cells stained by parental anti-
PSMA mAb, DB.PSMA x EGFR or control antibody DB.gp120 x gp41 respectively. Each data point is the mean ± SD of triplicates.
Fig. 5. BLI analysis of BsAb DB.PSMA x EGFR and BsAb controls for simultaneous binding to recombinant mEGFR and recombinant mPSMA. The BsAb association to
mEGFR loaded biosensors is displayed, followed by the association of mPSMA to the BsAb-EGFR complex for the various BsAb antibodies as indicated in the table.
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short, mEGFR recombinant protein was loaded on the biosensor, fol-
lowed by incubation of the various BsAbs to allow mEGFR specific
binding. Thereafter, the biosensors were incubated with mPSMA re-
combinant protein to assess binding of mPSMA to the mEGFR-BsAb
complex. As shown in Fig. 5, BsAb DB.PSMA x EGFR was able to bind
both antigens, recombinant mEGFR and mPSMA, at the same time.
Bispecific control DB.gp120 x EGFR showed only binding to mEGFR,
while bispecific control DB.PSMA x gp41 showed no binding activity
towards the mEGFR loaded biosensor (Fig. 5 and Supplementary
Fig. 2).
In addition, a cell bridging experiment was designed to test the
ability of BsAb DB.PSMA x EGFR and three bispecific control antibodies
to simultaneously bind to CHO/mEGFR and CHO/mPSMA cells. CHO/
mEGFR and CHO/mPSMA cells were stained with two different cell
staining dyes, subsequently mixed together at a 1:1 ratio, and incubated
with BsAb (DB.PSMA x EGFR) or control antibodies. Flow cytometry
results showed that only BsAb DB.PSMA x EGFR could serve as a bridge
binding CHO/mEGFR and CHO/mPSMA cells together to form cell
clusters in a dose dependent fashion leveling out at ~30% cell clusters
(Fig. 6). Although we quantified ~30% cellular cluster events, the
number of clustered cells is likely higher than 30% of total cells counted
because the flow cytometry set up did not enable distinguishing be-
tween doublets, triplets, or higher order cell clusters. Clustering by
BsAb is reported to be a direct function of absolute number of target
antigens expressed on each cell (Lopez-Albaitero et al., 2017; Oberst
et al., 2014; Laszlo et al., 2014) and although we detected ~20,000
target molecules on average for mPSMA and mEGFR on the respective
transfected clones (data not shown), a significant number of either
clonal population would display a number of antigens below the clus-
tering threshold. Moreover, stability of clustering is also determined by
fluid shear force leading to disruption of weakly formed clusters before
they pass the detector. Hence, a maximum of 100% cell clusters was not
expected.
Combined, these data show that the BsAb DB.PSMA x EGFR is
capable to simultaneously bind to its two antigens.
4. Discussion
Although the concept of BsAb has been used for a very long time,
the production and purification steps during BsAb development remain
one of the major challenges for their application to research and clinical
development. Specifically, heavy-light chain mis-pairing has remained
one of the major challenges to obtain pure BsAb. Approaches using a
common light chain, present a challenge when making use of already
pre-existing and validated antibodies (Merchant et al., 1998). Further-
more, approaches which introduce mutations at the contact points of
VH/VL or CH1/CL sometimes compromise the stability of the BsAb
(Atwell et al., 1997); while approaches that exchange the VH-VL or the
CH1-CL domains by domain crossover between the heavy and light
chain Fab domains can even damage antigen binding ability (Masuda
et al., 2006) (Chailyan et al., 2011) (Herold et al., 2017). All these
approaches require additional protein engineering and redetermination
of the physicochemical and biological characteristics of engineered
BsAb, making a standard mass production of novel bi-specific anti-
bodies challenging.
In the present study, we describe a novel approach to overcome
heavy-light chain mis-pairing, by establishing the Fab x sdAb-Fc format
of BsAb composed of a conventional antigen-binding fragment (Fab), a
single domain antibody (sdAb) and a mouse IgG2a Fc. We demonstrated
that the Fab x sdAb-Fc BsAb format can functionally be expressed and
assembled in a single FreeStyle™ 293-F host, using KIH and CP dimer-
ization strategies, or formed artificially by cFAE; reaching high purity
and retaining their capacity to bind both their target antigens si-
multaneously.
This format of BsAb also provides additional advantages for further
purification. As previously described, the Fab x sdAb-Fc format BsAbs
showed ~35 kDa MW difference from each parental antibody which is
sufficient for further separation based on size exclusion chromato-
graphy (SEC). Affinity chromatography might be another consideration
to further purify this format of BsAb. Affinity chromatography is a type
of chromatographic method used for purifying biological molecules
within a mixture based on highly specific biological interactions be-
tween two molecules, for instance, interactions between antibody and
antigen (Urh et al., 2009). Next, for the Fab x sdAb-Fc format, CH1
Fig. 6. Flow cytometry analysis of BsAbs inducing cellular clustering by simultaneous binding to CHO/mEGFR and CHO/mPSMA cells. (A-C) 1:1 mixed CHO/mEGFR
and CHO/mPSMA cells incubated with 390.63 nM bispecific control antibodies; (D) 1:1 mixed CHO/mEGFR and CHO/mPSMA cells incubated with increasing
concentration of DB.PSMA x EGFR. (E) Quantification of flow cytometry results by displaying the percentage of events that represents cellular clusters. Means± SD
of a representative experiment (n = 3) performed in triplicates are shown.
S. Huang, et al. Journal of Immunological Methods 483 (2020) 112811
8
selective chromatography can help to remove HcAbs. An IgG CH1 do-
main specific antibody could be conjugated to a resin to capture BsAb
and the parental antibody with CH1 domain, while HcAb can not bind,
in this way further improving the purity of BsAb.
In the presence study, the hinge between the sdAb and Fc was de-
signed to mimic the length of an entire CH1 domain, thus extending the
length of the sdAb arm similar to that of conventional Fab. However,
the hinge of the HcAb can be designed various for different applica-
tions. T cell-redirecting BsAbs with Fc might benefit from a short hinge
design. The distance between tumour cells and effector T cells has been
demonstrated essential for T cell mediated tumour cell killing (Bluemel
et al., 2010). A shorter distance between two arms can redirect T cells
closer to tumour cells which might lead to better tumour cell elimina-
tion. For targeting of tumour associated antigens the hinge of Fab x
sdAb-Fc BsAb can be optimized based on the distribution, density and
extracellular size of antigens with special attention to the distance be-
tween two antigens expressed on the tumour cell surface. Nevertheless,
how different hinges affect the functionality, stability and flexibility of
this format of BsAb still needs to be investigated further.
Taken together, we describe here a novel approach of constructing
bi-specific antibodies, which has a number of different advantages over
traditional approaches. It is foreseeable that the potential applications
for this format will only grow as the field of BsAb application in aca-
demic and clinical settings continues to evolve.
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